TREACE MEDICAL CONCEPTS, INC. (TMCI) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Low Risk
Limited dilution potential
Last updated: May 08, 2026

Risk Assessment Details

Potential Dilution: 14.51% of current shares
Recent Dilution: 4.19% (2 years)
Historical Dilution Factor: minimal recent dilution
Outstanding Shares
65M
Potential Supply
9.4M
Additional shares possible
Splits
None
Past 2 years

Summary

TMCI currently has 64.6M outstanding shares. with limited dilution risk as only 9.38M additional shares (14.5%) are authorized for issuance. The company has minimally diluted shareholders by 4.19% over the past 2 years.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 08, 2026

10-Q filing | 64.6M shares outstanding

65M 9.4M
Aug 07, 2025

10-Q filing | 63.0M shares outstanding

63M 9.4M
May 08, 2025

10-Q filing | 62.7M shares outstanding

63M 9.4M
Feb 27, 2025

10-K filing | 62.1M shares outstanding

62M 9.4M
Nov 05, 2024

10-Q filing | 62.2M shares outstanding

62M 9.4M
Aug 06, 2024

10-Q filing | 62.1M shares outstanding

62M 9.4M
May 07, 2024

10-Q filing | 61.8M shares outstanding

62M 9.4M
Feb 27, 2024

10-K filing | 60.9M shares outstanding

61M 9.4M
Nov 09, 2023

10-Q filing | 61.6M shares outstanding

62M 9.4M
Aug 09, 2023

10-Q filing | 61.4M shares outstanding

61M 9.4M
May 09, 2023

10-Q filing | 58.7M shares outstanding

59M 9.4M
Mar 08, 2023

10-K filing | 55.3M shares outstanding

55M 9.4M
Nov 09, 2022

10-Q filing | 55.4M shares outstanding

55M 9.4M
Aug 10, 2022

10-Q filing | 55.3M shares outstanding

55M 9.4M
May 06, 2022

10-Q filing | 55.3M shares outstanding

55M 9.4M
Mar 04, 2022

10-K filing | 54.7M shares outstanding

55M 9.4M
Nov 04, 2021

10-Q filing | 53.2M shares outstanding

53M 9.4M
Aug 05, 2021

10-Q filing | 52.8M shares outstanding

53M 9.4M
May 25, 2021

10-Q filing | 38.1M shares outstanding

38M 9.4M
Apr 19, 2021

S-1/A filing: This S-1/A filing relates to an offering of common stock by the company and selling stockholders, with an option for underwriters to purchase additional shares. The company intends to use the net proceeds to expand its sales force, develop new products, and for other general corporate purposes.

50M 9.4M
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime